ATE538776T1 - Träger zur freisetzung lipophilisches wirkstoffes und desen verwendungsverfahren - Google Patents

Träger zur freisetzung lipophilisches wirkstoffes und desen verwendungsverfahren

Info

Publication number
ATE538776T1
ATE538776T1 AT04711116T AT04711116T ATE538776T1 AT E538776 T1 ATE538776 T1 AT E538776T1 AT 04711116 T AT04711116 T AT 04711116T AT 04711116 T AT04711116 T AT 04711116T AT E538776 T1 ATE538776 T1 AT E538776T1
Authority
AT
Austria
Prior art keywords
release
carrier
active ingredients
bioactive agent
lipophilic active
Prior art date
Application number
AT04711116T
Other languages
English (en)
Inventor
Robert Ryan
Michael Oda
Original Assignee
Childrens Hosp & Res Ct Oak
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32912265&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE538776(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Childrens Hosp & Res Ct Oak filed Critical Childrens Hosp & Res Ct Oak
Application granted granted Critical
Publication of ATE538776T1 publication Critical patent/ATE538776T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT04711116T 2003-02-14 2004-02-13 Träger zur freisetzung lipophilisches wirkstoffes und desen verwendungsverfahren ATE538776T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US44750803P 2003-02-14 2003-02-14
US50803503P 2003-10-01 2003-10-01
PCT/US2004/004295 WO2004073684A2 (en) 2003-02-14 2004-02-13 Lipophilic drug delivery vehicle and methods of use thereof

Publications (1)

Publication Number Publication Date
ATE538776T1 true ATE538776T1 (de) 2012-01-15

Family

ID=32912265

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04711116T ATE538776T1 (de) 2003-02-14 2004-02-13 Träger zur freisetzung lipophilisches wirkstoffes und desen verwendungsverfahren

Country Status (9)

Country Link
US (4) US7824709B2 (de)
EP (2) EP1596828B1 (de)
JP (2) JP4777873B2 (de)
AT (1) ATE538776T1 (de)
AU (1) AU2004212944B2 (de)
CA (1) CA2515892C (de)
ES (1) ES2376875T3 (de)
TW (3) TWI433693B (de)
WO (1) WO2004073684A2 (de)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2376875T3 (es) 2003-02-14 2012-03-20 Children's Hospital & Research Center At Oakland Vehículo de administración de fármacos lipofílicos y métodos de utilización del mismo
CA2541117A1 (en) * 2003-10-01 2005-05-06 Children's Hospital & Research Center At Oakland Lipophilic drug delivery vehicle and methods of use thereof
TW200727900A (en) * 2005-07-27 2007-08-01 Yakult Honsha Kk Aqueous solution preparation containing camptothecins
US7875288B2 (en) * 2006-03-30 2011-01-25 The Research Foundation Of State University Of New York Method for treating blood coagulation disorders
AU2007235463B2 (en) * 2006-03-30 2012-11-22 The Research Foundation Of State University Of New York Compositions of less immunogenic and long-circulating protein-lipid complexes
EP2987456A1 (de) 2006-07-01 2016-02-24 Opus KSD, Inc. Chirurgische befestigungen und zugehörige einsetzvorrichtungen, und -mechanismen
US20090136937A1 (en) 2007-05-09 2009-05-28 Coleman Matthew A Methods and systems for monitoring production of a target protein in a nanolipoprotein particle
US9707274B2 (en) 2007-06-08 2017-07-18 Healthpartners Research & Education Methods for preventing and treating post-traumatic stress disorder (PTSD)
US8101565B2 (en) * 2007-09-20 2012-01-24 Abbott Cardiovascular Systems Inc. Sustained release of Apo A-I mimetic peptides and methods of treatment
US7985727B1 (en) 2007-09-20 2011-07-26 Abbott Cardiovascular Systems Inc. Apo A-I mimetic peptides and methods of treatment
US7985728B1 (en) 2007-09-20 2011-07-26 Abbott Cardiovascular Systems Inc. Sustained release of Apo A-I mimetic peptides and methods of treatment
US8044021B2 (en) * 2007-09-20 2011-10-25 Abbott Cardiovascular Systems Inc. Sustained release of apo A-I mimetic peptides and methods of treatment
US9173890B2 (en) * 2007-09-20 2015-11-03 Abbott Cardiovascular Systems Inc. Sustained release of Apo A-I mimetic peptides and methods of treatment
EP2092834A1 (de) * 2008-02-19 2009-08-26 Innopact B.V. Verfahren und Zusammensetzungen enthaltend Sphingolipid zur Verhinderung oder Behandlung mikrobieller Infektionen
EP2305309A2 (de) 2008-06-13 2011-04-06 Proyecto de Biomedicina Cima, S.L. Konjugate zur verabreichung von biologischen wirkstoffen
US8268796B2 (en) 2008-06-27 2012-09-18 Children's Hospital & Research Center At Oakland Lipophilic nucleic acid delivery vehicle and methods of use thereof
CA2730737A1 (en) * 2008-07-15 2010-01-21 Novartis Ag Immunogenic amphipathic peptide compositions
US9445975B2 (en) * 2008-10-03 2016-09-20 Access Business Group International, Llc Composition and method for preparing stable unilamellar liposomal suspension
WO2011005916A1 (en) * 2009-07-08 2011-01-13 William Marsh Rice University Nanoparticle compositions comprising a lipid bilayer and associated methods
US10525152B2 (en) 2009-10-09 2020-01-07 Signablok, Inc. Methods and compositions for targeted imaging
US12419839B2 (en) 2009-10-09 2025-09-23 Signablok, Inc. Methods and compositions for targeted delivery of protein fragments
US10894098B2 (en) 2012-04-09 2021-01-19 Signablok, Inc. Methods and compositions for targeted imaging
KR101132626B1 (ko) * 2009-10-12 2012-04-02 주식회사 녹십자 난용성 약물의 전달을 위한 고밀도지단백 나노입자의 제조방법
EP2368433B1 (de) * 2010-03-24 2014-05-07 Cognis IP Management GmbH Biozidzusammensetzungen, die Glycerin(ether)phosphate umfassen
US9644038B2 (en) 2011-12-21 2017-05-09 The Regents Of The University Of California Apolipoprotein nanodiscs with telodendrimer
US8895055B2 (en) * 2011-12-21 2014-11-25 The Regents Of The University Of California Telodendrimer nanodiscs without apolipoprotein
US9642916B2 (en) 2012-12-12 2017-05-09 The Regents Of The University Of California Porphyrin modified telodendrimers
ES2608857T3 (es) * 2012-12-18 2017-04-17 Salipro Biotech Ag Partículas Salipro
US9232943B2 (en) 2013-01-31 2016-01-12 Opus Ksd Inc. Delivering bioabsorbable fasteners
SI3043814T1 (sl) 2013-09-13 2021-04-30 Salipro Biotech AB, Greenhouse Labs Antigen in postopek za proizvodnjo le-tega
WO2015095854A1 (en) * 2013-12-20 2015-06-25 Discx Llc Novel nanodisc clathrates and uses thereof
CA2971519C (en) * 2014-12-22 2023-04-11 Consiglio Nazionale Delle Ricerche Products for the delivery of therapeutic/diagnostic compounds to the heart
US10596117B1 (en) * 2014-12-31 2020-03-24 Eric Morrison Lipoleosomes as carriers for aromatic amide anesthetic compounds
WO2017035326A1 (en) 2015-08-25 2017-03-02 Lawrence Livermore National Security, Llc Stable nanolipoprotein particles and related compositions methods and systems
US11279749B2 (en) 2015-09-11 2022-03-22 Lawrence Livermore National Security, Llc Synthetic apolipoproteins, and related compositions methods and systems for nanolipoprotein particles formation
EP3284460A1 (de) 2016-08-19 2018-02-21 Salipro Biotech AG Saposinlipoproteinpartikel und bibliotheken aus rohen membranen
CN110392583B (zh) 2016-09-15 2023-01-03 加利福尼亚大学董事会 改进的杂化的末端树枝状聚合物
WO2018064350A1 (en) * 2016-09-30 2018-04-05 Eriochem Usa, Llc Apo-e modified lipid nanoparticles for drug delivery to targeted tissues and therapeutic methods
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
WO2018181538A1 (ja) * 2017-03-31 2018-10-04 株式会社カネカ ナノディスクとその製造方法
US12083223B2 (en) 2017-05-02 2024-09-10 Lawrence Livermore National Security, Llc Nanolipoprotein particles and related compositions methods and systems for loading RNA
WO2018204421A2 (en) 2017-05-02 2018-11-08 Lawrence Livermore National Security, Llc Momp telonanoparticles, and related compositions, methods and systems
JP7330163B2 (ja) * 2017-07-07 2023-08-21 ドレクセル ユニバーシティ 電位活性化型の治療用構築物、診断用構築物、および／またはセラノスティック用構築物
US20190307892A1 (en) * 2018-04-04 2019-10-10 Eriochem Usa, Llc Targeted drug delivery and therapeutic methods using apo-e modified lipid nanoparticles
JP2021534101A (ja) 2018-08-09 2021-12-09 ヴェルソー セラピューティクス， インコーポレイテッド Ｃｃｒ２及びｃｓｆ１ｒを標的とするためのオリゴヌクレオチド組成物ならびにその使用
JP7620321B2 (ja) 2018-08-31 2025-01-23 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア シアニンベースをベースとするテロデンドリマー及び癌治療のための使用
EP3725304A1 (de) 2019-04-15 2020-10-21 Salipro Biotech AB Herstellung von salipro-partikeln
MX2021015667A (es) * 2019-06-28 2022-04-18 Univ Texas Metodo de reconstitucion de anamicina liposomica.
AU2020303572A1 (en) 2019-06-28 2022-01-20 Board Of Regents, The University Of Texas System Preparation of preliposomal Annamycin lyophilizate
DE202019003092U1 (de) * 2019-07-24 2020-01-17 Ruth-Maria Korth Test zur Bestimmung von Proteophospholipiden und FIDA-Formeln zur Bestimmung von Schutzfaktoren , die mit Substraten auszugleichen sind
US20240033322A1 (en) 2020-04-16 2024-02-01 Abionyx Pharma Sa Methods for treating acute conditions using lipid binding protein-based complexes
EP4221686A2 (de) 2020-10-01 2023-08-09 Abionyx Pharma SA Zusammensetzungen mit lipidbindenden komplexen auf proteinbasis zur verwendung zur behandlung von augenerkrankungen
EP4271483A4 (de) * 2020-12-30 2024-11-27 Lipotope, LLC Proteinstabilisierte liposome (psl) und herstellungsverfahren dafür
WO2022219413A1 (en) 2021-04-15 2022-10-20 Abionyx Pharma Sa Use of lipid binding protein-based complexes in organ preservation solutions
JP2025505427A (ja) * 2022-01-28 2025-02-26 リサーチ アンド ビジネス ファウンデーション サンキュンクワン ユニヴァーシティ 膜構造化タンパク質が結合している抗体を含む抗体結合脂質ナノ粒子
AU2023251245A1 (en) 2022-04-06 2024-11-14 Abionyx Pharma Sa Methods for treating leukocytosis, endothelial dysfunction and carditis using lipid binding protein-based complexes
JP2025511845A (ja) 2022-04-06 2025-04-16 アビオニクス ファーマ エスエー 脂質結合タンパク質ベースの複合体を使用した、眼疾患を治療するための方法
JP2025519606A (ja) 2022-06-10 2025-06-26 アビオニクス ファーマ エスエー 脂質結合タンパク質に基づく複合体を使用して急性状態を処置するための方法
IL317448A (en) 2022-06-10 2025-02-01 Abionyx Pharma Sa Methods for treating hyperinflammatory conditions using complexes based on lipid-binding proteins
KR102540330B1 (ko) * 2022-10-19 2023-06-05 엠브릭스 주식회사 인지질인 포스파티딜에탄올아민을 포함하는 나노디스크
JP2026505150A (ja) * 2022-12-19 2026-02-12 ベックマン コールター， インコーポレイテッド 脂質ベースのナノ粒子特性評価
JP2026504047A (ja) 2023-01-13 2026-02-03 アビオニクス ファーマ エスエー 脂質結合タンパク質分子療法
WO2025093929A1 (en) 2023-10-31 2025-05-08 Abionyx Pharma Sa Lipid binding protein molecule therapy

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US4970144A (en) 1984-12-31 1990-11-13 International Genetic Engineering Peptide fragments of human apolipoprotein, type-specific antibodies and methods of use
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
FR2609399A1 (fr) * 1987-01-13 1988-07-15 Ire Celltarg Sa Procede d'incorporation d'un ou plusieurs principes actifs lipophiles dans des lipoproteines, lipoproteines obtenues et composition pharmaceutique les contenant
US5166320A (en) 1987-04-22 1992-11-24 University Of Connecticut Carrier system and method for the introduction of genes into mammalian cells
US5128318A (en) † 1987-05-20 1992-07-07 The Rogosin Institute Reconstituted HDL particles and uses thereof
ATE133423T1 (de) † 1987-05-20 1996-02-15 Rogosin Inst Rekonstituierte hdl-teilchen und ihre verwendung
US5948441A (en) 1988-03-07 1999-09-07 The Liposome Company, Inc. Method for size separation of particles
FR2664500B1 (fr) * 1990-07-13 1994-10-28 Lille Ii Universite Droit Sant Procede de preparation d'une lipoproteine modifiee par incorporation d'une substance active lipophile, lipoproteine modifiee ainsi obtenue et composition pharmaceutique ou cosmetique la contenant.
US5874549A (en) 1990-09-28 1999-02-23 Neorx Corporation Acid-cleavable compound
WO1992009893A1 (en) 1990-11-29 1992-06-11 Carbaugh John E DIAGNOSTIC AND THERAPEUTIC COMPOSITIONS AND METHODS FOR LIPOPROTEIN(a)
US5733761A (en) 1991-11-05 1998-03-31 Transkaryotic Therapies, Inc. Protein production and protein delivery
US5576016A (en) * 1993-05-18 1996-11-19 Pharmos Corporation Solid fat nanoemulsions as drug delivery vehicles
US5744155A (en) 1993-08-13 1998-04-28 Friedman; Doron Bioadhesive emulsion preparations for enhanced drug delivery
US5514670A (en) 1993-08-13 1996-05-07 Pharmos Corporation Submicron emulsions for delivery of peptides
US5840707A (en) 1993-10-04 1998-11-24 Albany Medical College Stabilizing and delivery means of biological molecules
US7011827B2 (en) 1993-11-09 2006-03-14 Trustees Of The University Of Pennsylvania Compositions and methods for producing and using homogenous neuronal cell transplants
US5652339A (en) 1993-12-31 1997-07-29 Rotkreuzstiftung Zentrallaboratorium Method of producing reconstituted lipoproteins
US5746223A (en) 1996-10-11 1998-05-05 Williams; Kevin Jon Method of forcing the reverse transport of cholesterol from a body part to the liver while avoiding harmful disruptions of hepatic cholesterol homeostasis
JP4285766B2 (ja) * 1994-03-23 2009-06-24 オハイオ ユニバーシティ 緻密にした核酸および細胞へのデリバリ
US6440425B1 (en) 1995-05-01 2002-08-27 Aventis Pasteur Limited High molecular weight major outer membrane protein of moraxella
FR2734568B1 (fr) 1995-05-22 1997-06-20 Rhone Poulenc Rorer Sa Nouveaux variants de l'apolipoproteine
US5817789A (en) 1995-06-06 1998-10-06 Transkaryotic Therapies, Inc. Chimeric proteins for use in transport of a selected substance into cells
US5843474A (en) 1995-10-11 1998-12-01 Reverse Transport Licensing & Consulting, Inc. Method of dialysis treatment, and dialysis apparatus related thereto
US20020022053A1 (en) 1995-10-11 2002-02-21 Williams Kevin Jon Method of forcing the reverse transport of cholesterol from a body part to the liver while avoiding harmful disruptions of hepatic cholesterol homeostasis, and pharmaceutical compositions and kit related thereto
EP0935415B1 (de) 1996-05-01 2006-11-22 Imarx Pharmaceutical Corp. In vitro verfahren zum einbringen von nukleinsäuren in eine zelle
US6071493A (en) 1996-09-20 2000-06-06 Baylor College Of Medicine Method of screening for an agent that inhibits mononuclear phagocyte-plaque component complex formation
DE19640092A1 (de) 1996-09-28 1998-04-16 Beiersdorf Ag Strukturen mit Lipid-Doppelmembranen, in deren lipophilen Bereich längerkettige Moleküle eintauchen oder durch hydrophobe Wechselwirkungen an solche Moleküle angedockt sind
US6056973A (en) * 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
US6210707B1 (en) 1996-11-12 2001-04-03 The Regents Of The University Of California Methods of forming protein-linked lipidic microparticles, and compositions thereof
US6458373B1 (en) 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
DE19745950A1 (de) * 1997-10-17 1999-04-22 Dds Drug Delivery Service Ges Arzneistoffträgerpartikel für die gewebespezifische Arzneistoffapplikation
US20020051813A1 (en) * 1999-01-15 2002-05-02 Lawrence Boni Lipomatrix preparation
US6328988B1 (en) 1999-04-23 2001-12-11 Rutgers, The State University Of New Jersey Hyperbranched polymeric micelles for encapsulation and delivery of hydrophobic molecules
US20010031262A1 (en) 1999-12-06 2001-10-18 Michael Caplan Controlled delivery of antigens
WO2001056579A1 (en) 2000-02-04 2001-08-09 Esperion Therapeutics Inc. Methods for treating alzheimer's disease
US6514523B1 (en) * 2000-02-14 2003-02-04 Ottawa Heart Institute Research Corporation Carrier particles for drug delivery and process for preparation
EP1257576B1 (de) 2000-02-18 2004-09-15 Dabur Research Foundation Vip-analoge
AU2001257903A1 (en) 2000-03-22 2001-10-03 The General Hospital Corporation Method for treatment of neurodegenerative diseases
EP1265632A2 (de) 2000-03-24 2002-12-18 Biomira, Inc. Lipopeptid adjuvantien
US6696081B2 (en) 2000-06-09 2004-02-24 Duke University Carbohydrate based lipid compositions and supramolecular structures comprising same
DE10036694A1 (de) 2000-07-27 2002-02-14 Wacker Chemie Gmbh Verfahren zur Behandlung von organischen Fasern mit aminofunktionellen Organosiliciumverbindungen
CA2417744A1 (en) 2000-07-31 2002-02-07 The Regents Of The University Of California Model for alzheimer's disease and other neurodegenerative diseases
AU2002213843B2 (en) * 2000-11-10 2008-02-07 F. Hoffmann-La Roche Ltd. Apolipoprotein analogues
DK1345959T3 (da) 2000-11-20 2011-09-05 Univ Illinois Membranscaffoldproteiner
US7083958B2 (en) 2000-11-20 2006-08-01 The Board Of Trustees Of The University Of Illinois Membrane scaffold proteins
US7220833B2 (en) * 2002-12-03 2007-05-22 Thomas Nelson Artificial low-density lipoprotein carriers for transport of substances across the blood-brain barrier
ES2376875T3 (es) * 2003-02-14 2012-03-20 Children's Hospital & Research Center At Oakland Vehículo de administración de fármacos lipofílicos y métodos de utilización del mismo
CA2541117A1 (en) 2003-10-01 2005-05-06 Children's Hospital & Research Center At Oakland Lipophilic drug delivery vehicle and methods of use thereof
WO2005070400A1 (en) 2004-01-15 2005-08-04 Mount Sinai School Of Medicine Methods and compositions for imaging
US8268796B2 (en) 2008-06-27 2012-09-18 Children's Hospital & Research Center At Oakland Lipophilic nucleic acid delivery vehicle and methods of use thereof

Also Published As

Publication number Publication date
US20120309628A1 (en) 2012-12-06
US20100311595A1 (en) 2010-12-09
US7824709B2 (en) 2010-11-02
US9107826B2 (en) 2015-08-18
TWI369997B (en) 2012-08-11
US8821939B2 (en) 2014-09-02
TWI433693B (zh) 2014-04-11
JP2007063291A (ja) 2007-03-15
EP1596828B1 (de) 2011-12-28
CA2515892A1 (en) 2004-09-02
EP2314285B2 (de) 2019-09-18
AU2004212944B2 (en) 2008-08-21
JP2006517972A (ja) 2006-08-03
EP2314285A1 (de) 2011-04-27
EP1596828A2 (de) 2005-11-23
US20040229794A1 (en) 2004-11-18
EP2314285B1 (de) 2016-08-03
AU2004212944A1 (en) 2004-09-02
TW201424770A (zh) 2014-07-01
US20140308339A1 (en) 2014-10-16
JP4777873B2 (ja) 2011-09-21
WO2004073684A3 (en) 2004-11-11
TW201106988A (en) 2011-03-01
WO2004073684A2 (en) 2004-09-02
TW200509986A (en) 2005-03-16
ES2376875T3 (es) 2012-03-20
US8268357B2 (en) 2012-09-18
CA2515892C (en) 2012-10-23

Similar Documents

Publication Publication Date Title
ATE538776T1 (de) Träger zur freisetzung lipophilisches wirkstoffes und desen verwendungsverfahren
WO2005039534A8 (en) Lipophilic drug delivery vehicle and methods of use thereof
ATE554756T1 (de) Kombination aus epothilon-analog und chemotherapeutika zur behandlung von proliferativen erkrankungen
WO2005072710A3 (en) Drugs and gene carrier particles that rapidly move through mucous barriers
SI1345597T1 (sl) Amfifilni lipidni nanodelci za vgradnjo peptidov in/ali proteinov
ATE328573T1 (de) Behandlung und zusammensetzungen zur erzielung eines hautalterungsschutzes durch corneum protease aktivatoren
DE69942680D1 (de) Verfahren und Zusammensetzungen zur Prävention und Behandlung von Anämie
DE602005009344D1 (de) Verfahren und vorrichtung zur übertragung von leitenden teilen bei der herstellung von halbleiterbauelementen
MY128792A (en) Personal wash compositions containing particle-in-oil dispersion
WO2005120393A3 (en) Implantable device for drug delivery and improved visibility
IL170454A (en) Preparations of active ingredients for administration through the skin or through mucous membranes and their uses
DE60227095D1 (de) Zusammensetzungen und verfahren zur behandlung von abgebundenem gips
DE602006018583D1 (de) Verfahren und zusammensetzung zur behandlung von peripheren gefässkrankheiten
EP1303299A4 (de) Zusammensetzungen und methoden zur verstärkung der immunogenität von antigenen
WO2004063342A3 (en) Cellular delivery and activation polypeptide-nucleic acid complexes
WO2005099668A3 (en) Methods of manufacture and use of calcium phosphate particles containing allergens
UA88300C2 (ru) Гидрогелевые композиции, которые содержат интерферон
EP1853110A4 (de) Verfahren zur bereitstellung von verfügbarem zellmaterial aus peripherblut und zusammensetzung daraus
IL158691A0 (en) Solid orally-dispersible pharmaceutical formulation
WO2005020965A3 (en) Skeletally targeted nanoparticles
IL194775A (en) Medicinal products containing anti-secretory protein for use in the treatment of dysfunction of floating fat rafts and / or kowala and / or its prevention
DE602004019317D1 (de) Zubereitungen zur parenteralen Anwendung und verlängerte Freisetzung von Wirkstoffen
HUP0600778A2 (en) Synthetic human peptides and pharmaceutical compositions comprising them for the treatment of systemic lupus erythematosus
WO2010025435A3 (en) Controlled-released peptide formulations
EP1075184A4 (de) Zusammensetzungen und verfahren zur aktiven impfung